Search

Your search keyword '"Filippatos, Gerasimos"' showing total 21 results
Start Over Author "Filippatos, Gerasimos" Journal clinical research in cardiology
21 results on '"Filippatos, Gerasimos"'

1. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

Author

Čelutkienė, Jelena, Čerlinskaitė-Bajorė, Kamilė, Cotter, Gad, Edwards, Christopher, Adamo, Marianna, Arrigo, Mattia, Barros, Marianela, Biegus, Jan, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Léopold, Valentine, Deniau, Benjamin, Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Lam, Carolyn S. P., Voors, Adriaan A., Mebazaa, Alexandre, and Davison, Beth

Published
2024
Full Text
View/download PDF

2. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure

Author

de Koning, Marie-Sophie L. Y., Emmens, Johanna E., Romero-Hernández, Esteban, Bourgonje, Arno R., Assa, Solmaz, Figarska, Sylwia M., Cleland, John G. F., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Metra, Marco, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., Anker, Stefan D., Dickstein, Kenneth, Voors, Adriaan A., Lipsic, Erik, van Goor, Harry, and van der Harst, Pim

Published
2023
Full Text
View/download PDF

4. Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study

Author

Meyer, Sven, Teerlink, John R, Metra, Marco, Ponikowski, Piotr, Cotter, Gad, Davison, Beth A, Felker, G Michael, Filippatos, Gerasimos, Greenberg, Barry H, Hua, Tsushung A, Severin, Thomas, Qian, Min, and Voors, Adriaan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Cardiovascular, Aging, Good Health and Well Being, Acute Disease, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Dyspnea, Europe, Female, Heart Failure, Humans, Incidence, Injections, Intravenous, Length of Stay, Male, Prognosis, Recombinant Proteins, Relaxin, Sex Distribution, Sex Factors, Survival Rate, United States, Ventricular Function, Left, Serelaxin, Acute heart failure, Sex, Gender, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

AimsWomen with heart failure are typically older, and more often have hypertension and a preserved left ventricular ejection fraction as compared with men. We sought to analyze if these sex differences influence the course and outcome of acute heart failure.Methods and resultsWe analyzed sex differences in acute heart failure in 1161 patients enrolled in the RELAX-AHF study. The pre-specified study endpoints were used. At baseline, women (436/1161 patients) were older, had a higher left ventricular ejection fraction, a higher rate of hypertension, and were treated differently from men. Early dyspnea improvement (moderate or marked dyspnea improvement measured by Likert scale during the first 24 h) was greater in women. However, dyspnea improvement over the first 5 days (change from baseline in the visual analog scale area under the curve (VAS AUC) to day 5) was similar between men and women. Women reported greater improvements in general wellbeing by Likert, but no such benefits were evident with the VAS score. Multi-variable predictors of moderate or marked dyspnea improvement were female sex (p = 0.0011), lower age (p = 0.0026) and lower diuretic dose (p = 0.0067). The additional efficacy endpoints of RELAX-AHF were similar between men and women and serelaxin was equally effective in men and women.ConclusionsWomen exhibit better earlier dyspnea relief and improvement in general wellbeing compared with men, even adjusted for age and left ventricular ejection fraction. However, in-hospital and post-discharge clinical outcomes were similar between men and women. This trial is registered at ClinicalTrials.gov, NCT00520806.

Published
2017

5. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF

Author

Liu, Licette CY, Voors, Adriaan A, Teerlink, John R, Cotter, Gad, Davison, Beth A, Felker, G Michael, Filippatos, Gerasimos, Chen, Yakuan, Greenberg, Barry H, Ponikowski, Piotr, Pang, Peter S, Prescott, Margaret F, Hua, Tsushung A, Severin, Thomas M, and Metra, Marco

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Prevention, Heart Disease, Clinical Trials and Supportive Activities, Clinical Research, Kidney Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Acute Disease, Aged, Aged, 80 and over, Cardiovascular Agents, Female, Glomerular Filtration Rate, Heart Failure, Humans, Kaplan-Meier Estimate, Kidney, Kidney Diseases, Male, Middle Aged, Randomized Controlled Trials as Topic, Recombinant Proteins, Relaxin, Retrospective Studies, Time Factors, Treatment Outcome, Serelaxin, Acute heart failure, Renal function, Renal impairment, Number needed to treat, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundSerelaxin showed beneficial effects on clinical outcome and trajectories of renal markers in patients with acute heart failure. We aimed to study the interaction between renal function and the treatment effect of serelaxin.MethodsIn the current post hoc analysis of the RELAX-AHF trial, we included all patients with available estimated glomerular filtration rate (eGFR) at baseline (n = 1132). Renal impairment was defined as an eGFR

Published
2016

6. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction

Author

ter Maaten, Jozine M., Martens, Pieter, Damman, Kevin, Dickstein, Kenneth, Ponikowski, Piotr, Lang, Chim C., Ng, Leong L., Anker, Stefan D., Samani, Nilesh J., Filippatos, Gerasimos, Cleland, John G., Zannad, Faiez, Hillege, Hans L., van Veldhuisen, Dirk J., Metra, Marco, Voors, Adriaan A., and Mullens, Wilfried

Published
2020
Full Text
View/download PDF

8. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation

Author

Mordi, Ify R., Santema, Bernadet T., Kloosterman, Mariëlle, Choy, Anna-Maria, Rienstra, Michiel, van Gelder, Isabelle, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Hillege, Hans L., Metra, Marco, Ng, Leong L., Ouwerkerk, Wouter, Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zwinderman, Aeilko H., Zannad, Faiez, Voors, Adriaan A., and Lang, Chim C.

Published
2019
Full Text
View/download PDF

9. Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF

Author

Davison, Beth A, Cotter, Gad, Sun, Hengrui, Chen, Li, Teerlink, John R, Metra, Marco, Felker, G Michael, Voors, Adriaan A, Ponikowski, Piotr, Filippatos, Gerasimos, Greenberg, Barry, Teichman, Sam L, Unemori, Elaine, and Koch, Gary G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Acute Disease, Dose-Response Relationship, Drug, Endpoint Determination, Heart Failure, Humans, Randomized Controlled Trials as Topic, Relaxin, Retrospective Studies, Treatment Outcome, Heart failure, Statistics, Clinical trials, Phase II, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundClinically relevant endpoints cannot be routinely targeted with reasonable power in a small study. Hence, proof-of-concept studies are often powered to a primary surrogate endpoint. However, in acute heart failure (AHF) effects on surrogates have not translated into clinical benefit in confirmatory studies. Although observing an effect on one of many endpoints due to chance is likely, observing concurrent positive trends across several outcomes by chance is usually unlikely.MethodsPre-RELAX-AHF, which compared 4 relaxin doses with placebo in AHF, has shown favourable trends versus placebo (one-sided P

Published
2011

10. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF

Author

Cotter, Gad, Davison, Beth A., Butler, Javed, Collins, Sean P., Ezekowitz, Justin A., Felker, G. Michael, Filippatos, Gerasimos, Levy, Phillip D., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Voors, Adriaan A., Senger, Stefanie, Bharucha, David, Goin, Kathleen, Soergel, David G., and Pang, Peter S.

Published
2017
Full Text
View/download PDF

13. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity

Author

Parissis, John T., Andreoli, Chiara, Kadoglou, Nikolaos, Ikonomidis, Ignatios, Farmakis, Dimitrios, Dimopoulou, Ioanna, Iliodromitis, Efstathios, Anastasiou-Nana, Maria, Lainscak, Mitja, Ambrosio, Giussepe, Mebazaa, Alexandre, Filippatos, Gerasimos, and Follath, Ferenc

Published
2014
Full Text
View/download PDF

18. Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study

Author

Meyer, Sven, primary, Teerlink, John R., additional, Metra, Marco, additional, Ponikowski, Piotr, additional, Cotter, Gad, additional, Davison, Beth A., additional, Felker, G. Michael, additional, Filippatos, Gerasimos, additional, Greenberg, Barry H., additional, Hua, Tsushung A., additional, Severin, Thomas, additional, Qian, Min, additional, and Voors, Adriaan A., additional

Published
2016
Full Text
View/download PDF

19. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.

Author

Cotter, Gad, Davison, Beth A., Butler, Javed, Collins, Sean P., Ezekowitz, Justin A., Felker, G. Michael, Filippatos, Gerasimos, Levy, Phillip D., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Voors, Adriaan A., Senger, Stefanie, Bharucha, David, Goin, Kathleen, Soergel, David G., and Pang, Peter S.

Abstract

Introduction: TRV027, a ‘biased’ ligand of the angiotensin II type 1 receptor (AT1R), did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure (AHF) trial (BLAST-AHF).Methods: Post-hoc analyses from BLAST-AHF (n = 618) examined the effects of TRV027 by baseline systolic blood pressure (SBP) on changes in renal function and 180-day outcomes. Interactions between baseline SBP and select endpoints were identified utilizing a subpopulation treatment effect pattern plots (STEPP) analysis, then grouping of patients by SBP tertile: < 127, ≥ 127 to < 140, and ≥ 140 mmHg.Results: A trend towards increased creatinine in the first 3 days was noted in the lower SBP tertile, while in those in the higher two tertiles, TRV027, especially the 1 mg/h dose, reduced creatinine at days 5 and 30. Beneficial effects on 180-day all-cause mortality and cardiovascular (CV) death or readmission were observed in the two higher SBP tertiles (SBP ≥ 127 mmHg) in the TRV027 1 mg/h dose group (all-cause mortality HR 0.39, 95% CI 0.14–1.06, p = 0.056; CV death or HF/RF rehospitalization HR 0.53, 95% CI 0.28–1.01, p = 0.049), while more adverse outcomes were observed in patients in the lower SBP tertile.Conclusions: This post-hoc analysis of the BLAST-AHF study suggests contrasting effects of TRV027 by baseline SBP, with trends towards lower 180-day event rates in patients enrolled with higher baseline SBP, especially when given lower doses of TRV027. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

20. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors

Author

Letsas, Konstantinos P., primary, Efremidis, Michalis, additional, Kounas, Stavros P., additional, Pappas, Loukas K., additional, Gavrielatos, Gerasimos, additional, Alexanian, Ioannis P., additional, Dimopoulos, Nikolaos P., additional, Filippatos, Gerasimos S., additional, Sideris, Antonios, additional, and Kardaras, Fotis, additional

Published
2008
Full Text
View/download PDF

21. Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction

Author

Letsas, Konstantinos P., primary, Filippatos, Gerasimos S., additional, Pappas, Loukas K., additional, Mihas, Constantinos C., additional, Markou, Virginia, additional, Alexanian, Ioannis P., additional, Efremidis, Michalis, additional, Sideris, Antonios, additional, Maisel, Alan S., additional, and Kardaras, Fotios, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results